Immuneering IMRX
NASDAQ IMRX
$4.82 -0.22 (-4.37%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immuneering (IMRX) EV to FCF (2021 - 2026)

Analysis

Immuneering (IMRX) EV to FCF (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Immuneering 313.13 Mn 313.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.46
Mar 31, 2026 -9.95
Dec 31, 2025 -11.72
Sep 30, 2025 -4.18
Jun 30, 2025 -10.05
Mar 31, 2025 -1.34
Dec 31, 2024 -2.22
Sep 30, 2024 -1.98
Jun 30, 2024 1.88
Mar 31, 2024 -0.93
Dec 31, 2023 -10.84
Sep 30, 2023 -10.55
Jun 30, 2023 -17.33
Mar 31, 2023 -11.47
Dec 31, 2022 -1.91
Sep 30, 2022 -23.69
Jun 30, 2022 -1.53
Mar 31, 2022 -2.66
Dec 31, 2021 -7.67
Sep 30, 2021 -37.15